Related Experiment Videos
A "bad responder" to statins
Dirk Devroey1, W Betz, P Coigniez
1Department of General Practice, University of Brussels, Laarbeeklaan 103, B-1090 Brussels, Belgium. dirk.devroey@vub.ac.be
Insights
Pravastatin worsened cholesterol levels, but fenofibrate dramatically improved high-density lipoprotein cholesterol (HDL-C). Fenofibrate therapy resulted in a twofold increase in HDL-C compared to pravastatin.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Dyslipidemia management often involves statins.
- Pravastatin is a commonly prescribed statin for lowering cholesterol.
- Individual responses to lipid-lowering medications can vary significantly.
Observation:
- A patient experienced a significant worsening of lipid profiles, including high-density lipoprotein cholesterol (HDL-C), total cholesterol to HDL-C ratio, and low-density lipoprotein cholesterol to HDL-C ratio during pravastatin treatment.
- These adverse lipid changes persisted for three years despite pravastatin therapy.
Findings:
- Switching from pravastatin to fenofibrate led to a remarkable improvement in lipid parameters.
- High-density lipoprotein cholesterol (HDL-C) levels at least doubled after initiating fenofibrate compared to the levels observed during pravastatin treatment.
Implications:
- Fenofibrate may be a more effective alternative for patients with specific lipid metabolism issues unresponsive or poorly responsive to pravastatin.
- This case highlights the importance of personalized treatment strategies in managing dyslipidemia.
- Further research could explore the mechanisms behind differential responses to statins and fibrates in lipid management.
Abstract:
We report the case of a man whose high-density lipoprotein cholesterol (HDL-C) and the ratios of total cholesterol to HDL-C and low-density lipoprotein cholesterol to HDL-C worsened dramatically during pravastatin treatment. After 3 years, pravastatin was replaced by fenofibrate. The result was spectacular. The HDL-C increased to at least twice the level obtained during pravastatin.